HA-40 is an antineoplastic immunotherapeutic drug with anticarcinogenic and cytostatic effects.
Release form and composition
The drug is available in the form of a lyophilized powder for solution preparation.
One bottle of HA-40 contains:
- 1 ml of chromatographically purified standardized combination of polypeptides isolated from plant material, namely, extract (1:40) Polgonatum varticillatum (kupeny annulate);
- Inactive ingredients: potassium dihydrogen phosphate and sodium chloride.
Indications for use
According to the instructions for HA-40, the use of the drug is shown:
- In the treatment of malignant tumors.
HA-40 in many cases can improve the condition of patients who have advanced tumor processes, in whose treatment the possibilities of the main traditional therapies have been exhausted. The drug has a double effect on tumor formations: direct necrotic on neoplasms of epithelial tissues of all organs (on carcinomas) and indirectly on tumors of all types, except for some forms of leukemia. HA-40 slows down the development of malignant cells, promotes regression of formations and resorption of metastases, reduces pain, improves the quality of life and significantly increases its duration.
- Before surgery.
In this case, the drug is prescribed because during the formation of a primary malignant tumor there may be hidden metastases (according to statistics, in about 70% of cases), although their progression is suppressed by this primary tumor, which, moreover, reduces, and sometimes even "disables" anti-tumor mechanisms of the immune system. HA-40, according to the instructions, helps to normalize the immune system, promotes the resorption of hidden metastases, so that the primary tumor becomes localized.
- After surgery.
In this case, HA-40 is recommended for the reason that postoperative stress (especially in the first week after surgery) in most cases significantly reduces immunity, which increases the risk of new metastasis and the development of infections. The use of HA-40 in the postoperative period allows you to prevent the spread of metastases and speed up the healing process.
- Before the start of chemotherapy and radiation therapy, during their conduct, after completion.
Chemotherapy and radiotherapy have a toxic effect on the human cancer patient’s body, which can cause severe complications, which often leads to delaying treatment or even stopping it. Another problem is the initial resistance of individual tumor cells to the drugs used and the resistance acquired during treatment. In addition, radiation and chemotherapy cause genetic mutations in normal cells, resulting in a higher likelihood of the formation of qualitatively new types of tumors. So, the use of HA-40 before, in combination and after chemotherapy and radiotherapy can significantly reduce their toxic manifestation, thereby increasing the efficiency and the possibility of using these therapies. In addition, the human body is protected from the emergence of new tumors.
- In the treatment of certain types of leukemia.
As a single agent or in combination with other types of therapy, HA-40 is used in the treatment of megakaryoblastic and myeloblastic leukemias. In this case, the stimulation of the processes of hematopoiesis (hematopoiesis), the degeneration of malignant cells in normal.
In addition, HA-40 is used in the treatment of:
- Allergic diseases, including bronchial asthma;
- Benign and other formations - fibroids, cystosis, adenoma, fibroma, mastitis, etc .;
- Infectious and inflammatory diseases, including acute and chronic viral hepatitis (A, B and C), cirrhosis of different origin, bronchitis, pneumonia, tuberculosis, cholecystitis, gastric and duodenal ulcers, prostatitis, cystitis, toxoplasmosis, chlamydiosis, trichomoniasis, etc.
HA-40 is recommended for safe prophylactic treatment of people with a genetic susceptibility to tumor formations, which are closely associated with adverse environmental factors, weakened or inadequate immunity.
HA-40 can also be used to increase the body's resistance to viral and other infectious diseases, especially in people over the age of 40-50 years.
The use of HA-40 is contraindicated:
- With increased sensitivity to the components of the drug;
- During pregnancy.
Dosing and Administration
A solution of HA-40, prepared from a lyophilisate (the contents of 1 bottle is diluted with 5 ml of injection water), is intended for intramuscular or subcutaneous injections.
The dose of one injection is 0.01 ml (2 μg) for each kilogram of patient weight. One course of treatment consists of 21 injections (at a minimum), the therapy is carried out according to the scheme prescribed by the doctor.
The duration of treatment in each case is determined individually, as a rule, by the time of remission of the tumor or another disease. Usually, complete therapy involves 7 courses with breaks from 3 to 14 days (which depends on the diagnosis, the severity of the condition and the dynamics of treatment). Then the patient is recommended one-time repeated prophylactic courses at intervals of 2-4 months.
In order to reduce the risk of developing nonspecific and oncological diseases, as well as to increase the body's resistance to viral and infectious diseases, it is shown to conduct one course twice a year.
The only possible side effect of HA-40 is an allergic reaction.
There are no structural analogues of GA-40.
Terms and conditions of storage
According to the manufacturer’s recommendations, HA-40 should be stored in a dark place at a temperature of 4 to 10 ºС. Under these conditions, the shelf life of the lyophilisate is 12 months.